Physician profile
Sandra J Utter
NPI 1679712681
$12,026.55
in general payments reported to CMS, 2019-2025
51 companies · $2,143 in 2025
The $2,143 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,459 · 2020: $1,199 · 2021: $1,369 · 2022: $1,553 · 2023: $1,905 · 2024: $2,398 · 2025: $2,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,446.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,251.39 | 2019-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $1,274.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,011.18 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $602.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $599.27 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $594.33 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $478.50 | 2019-2025 | Rexulti |
| Pfizer INC. | $417.84 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $395.19 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.99 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.92 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $292.93 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $263.90 | 2019-2024 | Verquvo, Gardasil 9, Vaxelis |
| Allergan, INC. | $243.77 | 2019-2020 | |
| Astellas Pharma US INC | $203.11 | 2019-2024 | Myrbetriq, Veozah |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Utter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.